Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Immunotherapy|February 17, 2025
Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myelomaSophie Carlson, Tasha L Lin, Sarah M Larson
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2022
Moving Toward a Cure for MyelomaMaría-Victoria Mateos, Ajay K Nooka, Sarah M Larson
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 24, 2021
Cost-Health Literacy as an Educational Objective in Fellowship TrainingKatrina A Fischer, Sidharth Anand, Anne Walling, et al.
Nature Reviews. Cardiology|February 23, 2026
Cardiotoxicity of T cell immunotherapiesMichael A Raddatz, Ashley F Stein-Merlob, Syed S Mahmood, et al.
Human Vaccines & Immunotherapeutics|January 7, 2017
Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapySarah M Larson, Laurel C Truscott, Tzu-Ting Chiou, et al.
Cancer|May 20, 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3Ajay K Nooka, Christopher Strouse, Sarah M Larson, et al.
Annals of Hematology|March 28, 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndromeGuillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, et al.
American Journal of Cancer Research|July 12, 2021
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myelomaRobert F Cornell, Michael R Bishop, Shaji Kumar, et al.
British Journal of Haematology|May 29, 2023
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREENeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
Leukemia & Lymphoma|September 15, 2011
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML)Sarah M Larson, Nicholas P Campbell, Dezheng Huo, et al.
Pageof 2